1000 WINTER ST, SUITE 1200, WALTHAM, MA
Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Zenas BioPharma Completes $200 Million Convertible Notes Offering
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Annual Report to Security Holders
Zenas BioPharma Approves Amended Short-Term Incentive Plan
Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Q2
Q1
FY 2025
FY 2024
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13D - Ownership Report
Free Writing Prospectus
Prospectus filed pursuant to Rule 424(b)(7)